LEXX vs. OVID, GBIO, RENB, ZVRA, PRLD, IVA, CAPR, IXHL, ABEO, and GLSI
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Ovid Therapeutics (OVID), Generation Bio (GBIO), Renovaro (RENB), Zevra Therapeutics (ZVRA), Prelude Therapeutics (PRLD), Inventiva (IVA), Capricor Therapeutics (CAPR), Incannex Healthcare (IXHL), Abeona Therapeutics (ABEO), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical preparations" industry.
Ovid Therapeutics (NASDAQ:OVID) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.
Ovid Therapeutics received 343 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 70.55% of users gave Ovid Therapeutics an outperform vote.
Ovid Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Lexaria Bioscience has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -10,691.14%. Lexaria Bioscience's return on equity of -53.62% beat Ovid Therapeutics' return on equity.
Ovid Therapeutics currently has a consensus target price of $8.08, suggesting a potential upside of 173.09%. Lexaria Bioscience has a consensus target price of $12.00, suggesting a potential upside of 266.97%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Ovid Therapeutics.
Lexaria Bioscience has higher revenue and earnings than Ovid Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 13.3% of Ovid Therapeutics shares are held by company insiders. Comparatively, 7.6% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Lexaria Bioscience had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 1 mentions for Lexaria Bioscience and 0 mentions for Ovid Therapeutics. Lexaria Bioscience's average media sentiment score of 0.00 equaled Ovid Therapeutics'average media sentiment score.
Summary
Lexaria Bioscience beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
